- Dr. William Cho, PhD, Charted Scientist
- Department of Clinical Oncology, Queen Elizabeth Hospital, Hong Kong, China.
- Dr. Fuquan Yang, MD, PhD, Principal Investigator, Director of Laboratory of Proteomics
- Key Laboratory of Protein and Peptide Pharmaceuticals & Laboratory of Proteomics, Institute of Biophysics, Chinese Academy of Sciences, Beijing, China.
Website | E-mail
Special Issue Introduction
Drug resistance is a major hurdle for cancer treatment and may account for the cancer mortality. In the precision oncology era, oncologists wish to have a better prediction for the treatment response so as to tailor-make the best personalized regime for individual cancer patients. Thanks to the advent of high-throughput platforms and clinical trials which accompany with biomarker research, we have a better understanding of the mechanisms behind the drug resistance and hopefully have robust predictive biomarkers for this important area. Indeed, the genomic, transcriptomic, and proteomic development identifies a large number of potential biomarkers. We envision some of them may assist real-time clinical decision-making to maximize therapeutic efficacy.
This special issue serves as a platform for the seasoned scholars to update in the development in this field. The scope of this special issue will cover from bench to bedside applications. Potential biomarker development, translational and multi-omics research are welcome.
KeywordsCancer, drug resistance, multi-omics, precision oncology, predictive biomarker
Submission Deadline30 Nov 2020